Forkhead Box Transcription Factor 1 Expression in Gastric Cancer: FOXM1 is a Poor Prognostic Factor and Mediates Resistance to Docetaxel

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2013 Sep 6

PMID 24004449

Citations 30

Authors

Xiaoxiao Li

Wensheng Qiu

Bin Liu

Ruyong Yao

ShiHai Liu

Yasai Yao

Jun Liang

Affiliations

Soon will be listed here.

Abstract

Background: Forkhead box transcription factor 1 (FOXM1) has been reported to overexpress and correlate with pathogenesis in a variety of human malignancies. However, little research has been done to investigate its clinical significance in gastric cancer.

Methods: We examined the expression of FOXM1 in 103 postoperational gastric cancer tissues and 5 gastric cell lines by immunohistochemistry and western blot analysis respectively. Data on clinic-pathological features and relevant prognostic factors in these patients were then analyzed. Moreover, the association of FOXM1 expression and chemosensitivity to docetaxel in gastric cancer cells was further explored.

Results: Our study demonstrated that the level of FOXM1 expression was significantly higher in gastric cancer than in para-cancer tissues (P < 0.001) and normal gastric cell lines (P = 0.026). No significant association was found between FOXM1 expression and any clinical pathological features (P > 0.1). FOXM1 amplification was identified as an independent prognostic factor in gastric cancer (P = 0.001), and its affection is more significant in patients with tumor size larger than 5 cm (P = 0.004), pT3-4 (P = 0.003) or pIII-IV (P = 0.001). Additionally, shown to mediate docetaxel resistance in gastric cancers by our research, FOXM1 was revealed to alter microtubule dynamics in response to the treatment of docetaxel, and the drug resistance could be reversed with FOXM1 inhibitor thiostrepton treatment.

Conclusions: FOXM1 can be a useful marker for predicting patients' prognosis and monitoring docetaxel response, and might be a new therapeutic target in docetaxel resistant gastric cancer.

Citing Articles

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.

Lingo J, Voigt E, Quelle D Oncotarget. 2024; 15:638-643.

PMID: 39347707 PMC: 11441412. DOI: 10.18632/oncotarget.28650.

Thiostrepton induces spindle abnormalities and enhances Taxol cytotoxicity in MDA-MB-231 cells.

Kuo H, Yao J, Yih L Mol Biol Rep. 2024; 51(1):927.

PMID: 39168955 PMC: 11339111. DOI: 10.1007/s11033-024-09863-1.

Gastric coinfection with thiopeptide-positive decreases FOXM1 and pro-inflammatory biomarker expression in a murine model of -induced gastric cancer.

Lunger C, Shen Z, Holcombe H, Mannion A, Dzink-Fox J, Kurnick S Microbiol Spectr. 2023; 12(1):e0345023.

PMID: 38014984 PMC: 10783005. DOI: 10.1128/spectrum.03450-23.

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy.

Voigt E, Quelle D Int J Mol Sci. 2023; 24(17).

PMID: 37686402 PMC: 10487994. DOI: 10.3390/ijms241713596.

c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.

Wang W, Shang Y, Wang C, Ni J, Wang A, Li G Acta Pharmacol Sin. 2022; 43(11):2956-2966.

PMID: 35422085 PMC: 9622852. DOI: 10.1038/s41401-022-00905-7.

References

Wang I, Chen Y, Hughes D, Petrovic V, Major M, Park H . Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005; 25(24):10875-94. PMC: 1316960. DOI: 10.1128/MCB.25.24.10875-10894.2005. View

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K . Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol. 2012; 20(3):1035-43. DOI: 10.1245/s10434-012-2680-0. View

Park S, Chun J, Kim Y, Lee J, Choi I, Kim C . Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005; 28(5):433-8. DOI: 10.1097/01.coc.0000162424.69631.79. View

Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T . Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007; 18(10):1673-9. DOI: 10.1093/annonc/mdm269. View

Katoh Y, Katoh M . Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med. 2009; 9(7):873-86. DOI: 10.2174/156652409789105570. View

Van Cutsem E, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429. View

Ma R, Tong T, Leung W, Yao K . Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol. 2010; 647:113-23. DOI: 10.1007/978-1-60761-738-9_6. View

Yau C, Wang Y, Zhang Y, Foekens J, Benz C . Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat. 2011; 126(3):803-10. PMC: 4337964. DOI: 10.1007/s10549-011-1345-1. View

Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G . Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res. 2003; 23(5b):4219-22. View

10.

Ajani J, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(22):3210-6. DOI: 10.1200/JCO.2006.08.3956. View

11.

Chen C, Chien C, Huang C, Hwang C, Chuang H, Fang F . Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009; 28(30):2723-37. DOI: 10.1038/onc.2009.128. View

12.

Carr J, Park H, Wang Z, Kiefer M, Raychaudhuri P . FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 2010; 70(12):5054-63. PMC: 2893542. DOI: 10.1158/0008-5472.CAN-10-0545. View

13.

Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L . The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 2013; 32(3):106-12. PMC: 3845591. DOI: 10.5732/cjc.013.10018. View

14.

Liu M, Dai B, Kang S, Ban K, Huang F, Lang F . FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006; 66(7):3593-602. DOI: 10.1158/0008-5472.CAN-05-2912. View

15.

Ajani J . Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park). 2002; 16(6 Suppl 6):89-96. View

16.

Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N . Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep. 2007; 18(2):329-36. View

17.

Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D . Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009; 69(8):3501-9. PMC: 4087044. DOI: 10.1158/0008-5472.CAN-08-3045. View

18.

Oh D, Kim T, Kwon J, Lee J, Joh Y, Kim D . Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol. 2005; 35(7):380-5. DOI: 10.1093/jjco/hyi107. View

19.

Tebbutt N, Cummins M, Sourjina T, Strickland A, Van Hazel G, Ganju V . Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010; 102(3):475-81. PMC: 2822950. DOI: 10.1038/sj.bjc.6605522. View

20.

Ajani J, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(22):3205-9. DOI: 10.1200/JCO.2006.10.4968. View